Real world analyses of patients with coronary artery disease (CAD) or heart failure (HF) have highlighted Lp(a) as an independent risk factor for adverse cardiovascular (CV) outcomes.1,2
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
